| Name | BAY-069 |
| Description | BAY-069 is an inhibitor. BAY-069 inhibited branched-chain amino acid transaminase 1 (BCAT1) at IC50:31 nM and branched-chain amino acid transaminase 2 (BCAT2) at IC50:153 nM. BAY-069 is a novel (trifluoromethyl) pyrimidine dione chemical probe, which can be used for anticancer research. |
| In vitro | BAY-069, inhibits the proliferation of U-87 and MDA-MB-231 cells. The compound is tested at concentrations ranging from 70 nM to 50 μM, with a duration of 72 hours. In U-87 cells, the IC50 is determined to be 358 nM, while in MDA-MB-231 cells, the IC50 is 874 nM [1]. |
| In vivo | BAY-069 demonstrates high metabolic stability when incubated with human liver microsomes, with a blood clearance of 0.11 L/h/kg. It also shows moderate metabolic stability when incubated with rat hepatocytes, with a blood clearance of 1.8 L/h/kg. BAY-069 exhibits high permeability through Caco-2 cell monolayers without any signs of efflux [1]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 150 mg/mL (335.71 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (11.19 mM), Sonication is recommended.
|
| Keywords | ReactiveOxygenSpecies | Reactive Oxygen Species | BCAT | BAY-069 | BAY069 | BAY 069 |
| Inhibitors Related | Ethoxyquin | Cysteamine hydrochloride | Acetylcysteine | L-Ascorbic acid | Dimethyl fumarate | Glucosamine | D-(+)-Glucono-1,5-lactone | L-Cystine | (-)-Epigallocatechin Gallate | L-Ascorbic acid sodium salt | Sodium 2-oxopropanoate | Arecoline |
| Related Compound Libraries | Bioactive Compound Library | Anti-Ovarian Cancer Compound Library | Anti-Obesity Compound Library | Inhibitor Library | Mitochondria-Targeted Compound Library | Metabolism Compound Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | Anti-Cancer Active Compound Library | Oxidation-Reduction Compound Library |